- Research article
- Open Access
Childhood-onset primary Sjögren’s syndrome in a tertiary center in China: clinical features and outcome
Pediatric Rheumatology volume 21, Article number: 11 (2023)
To characterize the clinical features and outcomes of childhood-onset primary Sjögren’s syndrome (pSS).
Patients less than 18 years old who were diagnosed with pSS by paediatric rheumatologists were included, and all patients were applied the 2002 American-European Consensus Group (ACEG) criteria, the 2016 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) criteria for pSS, or the 1999 proposed juvenile pSS criteria. The electronic medical records of patients with pSS from 2013 to 2020 were collected and analysed.
Thirty-nine patients were included. Of them, 27 (69.2%), 38 (97.4%) and 35 (89.7%) patients fulfilled the AECG criteria, ACR/EULAR criteria and proposed juvenile pSS criteria, respectively. The female:male ratio was 3.9:1. The median ages at first signs or symptoms and at diagnosis were 9.2 (4.7, 14.5) years and 10.9 (6.3, 15.0) years, respectively. The main clinical manifestations were rash or purpura (20, 51.3%), followed by fever (12, 30.8%), glandular enlargement/recurrent parotitis (10, 25.6%), and dry mouth and/or dry eyes (9, 23.1%). Twenty-eight (56.4%) patients had systemic damage, the most common of which was haematological involvement (14, 35.9%), followed by hepatic (13, 33.3%) and renal involvement (8, 20.5%). Thirty-eight (97.4%) patients underwent labial minor salivary gland biopsy, and all exhibited focal lymphocytic sialadenitis. All patients had a global ESSDAI score ≥ 1 at diagnosis, and the median total score at diagnosis was 8 (2, 31). Thirty-six (92.3%) patients were followed up for a median time of 23.6 (7.9, 79.5) months, and three patients developed systemic lupus erythematosus (SLE) at follow-up times of 13.3, 38.8 and 63.8 months.
The presentation of childhood-onset pSS is atypical, and extraglandular manifestations and systemic involvement are more common than in adult-onset pSS. Labial salivary gland biopsy is vital for patients with probable pSS. Some patients may develop SLE over time.
Primary Sjögren’s syndrome (pSS) is a systemic autoimmune disease, predominantly affects middle-aged women, with a frequency ranging between 0.01 and 0.72% . Patients with pSS mainly experience oral and ocular dryness and extraglandular manifestations (EGM), including interstitial pneumonitis, interstitial nephritis, isosthenuria or renal tubular acidosis, thyroiditis, central nervous system involvement, vasculitis, and an increased incidence of lymphoma .
In children, pSS is less well characterized in terms of clinical presentation and long-term outcomes . When the disease starts before the age 18 of years, it is called SS with childhood onset or juvenile SS. Childhood-onset pSS is rarely reported, poorly defined and possibly underdiagnosed due to the different criteria used for diagnosis and the scarcity of available data . A recent report of the Sjogren Big Data Consortium revealed that childhood-onset pSS involved approximately 1% of patients with pSS, with a clinical phenotype dominated by sicca features, parotid enlargement, and the highest frequencies of systemic disease in 5 (constitutional, lymphadenopathy, glandular, cutaneous and haematological) of the 12 European League Against Rheumatism (EULAR) Sjögren's syndrome disease activity index (ESSDAI) domains .
Neither of the currently most widely used classification criteria of pSS, the American-European Consensus Group (AECG) criteria  and the American College of Rheumatology/EULAR criteria , have been validated in a juvenile population. Child-specific criteria have been proposed ; however, even these criteria have a sensitivity of only 76% for diagnosing childhood SS [9, 10].
In the absence of established classification criteria specific for pSS in children, we chose to focus our study on children who met any of the current classification criteria [6, 7, 8]. Therefore, the aim of this study was to characterize the clinical features, immunological profiles and long-term outcomes of childhood-onset pSS in a cohort of Chinese patients from a tertiary paediatric medical centre.
In this retrospective longitudinal cohort study, patients who were diagnosed with pSS by paediatric rheumatologists with an onset age of 18 years or younger were included. Patients who were suspected of having secondary SS were excluded. At the time of inclusion, all patients were applied the AECG criteria , the ACR/EULAR criteria , or the 1999 proposed diagnostic criteria for juvenile pSS . The electronic medical records of patients with new-onset pSS from the Children’s Hospital of Fudan University, Shanghai, China, between January 2013 and December 2020 were screened. Children’s Hospital of Fudan University is one of the three National Children's Hospital centres, and all data collected were reliable and complete. The following clinical variables were selected for analysis:
Epidemiological features: age (age at onset and at diagnosis) and gender.
Clinical features: disease course and initial and main symptoms and/or signs suggesting an autoimmune disease.
Systemic activity: systemic involvement at diagnosis was classified and scored according to the EULAR ESSDAI . The haematological and biological domains were determined from the most recent blood samples available.
Immunological profile: antinuclear antibodies (ANA), anti-Ro(SSA)/La(SSB) antibodies, complement C3 and C4 levels, anti-double strand DNA antibody (anti-dsDNA antibody), serum immunoglobulin G (IgG), rheumatoid factor (RF) and erythrocyte sedimentation rate (ESR).
Histological data: labial minor salivary gland (LSG) biopsy.
Outcome (for patients followed for more than 1 year): developed to SLE or progressed to Lymphoma.
The observation end point was the last follow-up record in our centre.
The study was approved by the Research Ethics Board of Children’s Hospital of Fudan University and carried out in accordance with the guidelines of the Declaration of Helsinki. Patients who agreed to participate gave their written informed consent.
Descriptive data are presented as medians (ranges) for enumerated data and numbers and percentages (%) for categorical variables. The chi-square test was used to compare categorical variables. All analyses were performed using IBM SPSS Statistics version 26.0 (Armonk, NY, IBM Corp).
Our cohort consisted of 39 patients. The female:male ratio was 3.9:1 (31:8). The median age at the first sign or symptom suggestive of the disease and at the time of diagnosis of pSS were 9.2 (4.7, 14.5) years and 10.9 (6.3,15.0) years, respectively. The time interval from onset to diagnosis was 6.5 (0.4, 72.9) months (Table 1).
Out of the 39 patients, 27 (69.2%), 38 (97.4%) and 35 (89.7%) fulfilled the AECG criteria, ACR/EULAR criteria and proposed juvenile pSS criteria, respectively. Thirty-eight (97.4%) patients fulfilled either the AECG or ACR/EULAR criteria, 37 (94.8%) patients fulfilled either the AECG criteria or the proposed juvenile pSS criteria, and all patients fulfilled either the ACR/EULAR or the proposed juvenile pSS criteria (Table 1).
In our cohort, the main clinical manifestations were skin involvement [20 (51.3%), including rash (erythema, urticaria, etc.) (12, 30.8%), and purpura (8, 20.5%)], followed by fever (12, 30.8%), glandular enlargement/recurrent parotitis (10, 25.6%), and dry mouth and/or dry eyes (9, 23.1%). The main manifestations of pSS diagnosed in childhood are summarized in Table 2.
Twenty-eight (56.4%) patients presented with essential systemic damage, the most common of which was haematological involvement [14 (35.9%), including leukopenia (7,17.9%), thrombocytopenia (6, 15.4%), and anaemia (4,10.3%)], followed by hepatic involvement [13 (33.3%), mainly manifested as elevated liver enzymes, especially one patient with cirrhosis and cholestasis] and renal involvement [8 (20.5%), including renal tubular acidosis (RTA) (4, 10.3%), proteinuria (4, 10.3%) and renal impairment (3, 7.7%)]. Of them, one patient initially manifested with elevated leucocytes and jaundice and was diagnosed with pSS combined with cholestasis, RTA, proteinuria [renal biopsy confirmed focal proliferative glomerulonephritis with mild tubulointerstitial nephritis (TIN)], lower limb peripheral neuropathy and 47,XXX (Fig. 1). In addition, the initial symptom/sign at onset in one patient was uveitis, not dry eye. Three patients had interstitial pneumonia (Table 2).
In total, four patients underwent renal biopsy, one of whom was described above. In the second patient, the initial symptom/sign at onset was Raynaud phenomenon and arthralgia combined with ANA and SSA positivity and low C3 levels, and the renal pathological result was focal proliferative glomerulonephritis, differentiating it from SLE. The last two patients were confirmed to have lupus nephritis by biopsy when suspected of having SLE during the follow-up period.
Diagnostic tests, immunological markers and systemic activity
With respect to the diagnostic approach, abnormal ocular tests were reported in 24.3% (9/37) of those studied using corneal fluorescein staining, and abnormal oral tests were reported in 81.5% (22/27) of those studied by parotid scintigraphy. Unfortunately, we could not evaluate Schirmer’s test, conjunctival lissamine green staining, or unstimulated whole salivary flows. Thirty-eight (97.4%) patients underwent LSG biopsy, and all exhibited focal lymphocytic sialadenitis with a focus score of ≥ 1 focus/4 mm2 (Table 3).
For the immunological profile at the time of diagnosis, the most frequent abnormalities consisted of anti-Ro/SSA antibody positivity (39, 100%), ANA positivity (37, 94.9%), polyclonal hyperimmunoglobulinaemia (35, 89.7%), and a high ESR (27, 69.2%). None of the patients were positive for anti-dsDNA antibodies (Table 3).
Regarding systemic phenotype, the median total ESSDAI score at diagnosis of our cohort was 8 (2, 31), and all patients had systemic activity at diagnosis (global ESSDAI score ≥ 1). According to the EULAR definition, 8 patients had inactive disease (ESSDAI score < 5) at diagnosis. The frequently involved ESSDAI domains at diagnosis were biological (79.5%), followed by the cutaneous (35.9%), constitutional (28.2%), haematological (28.2%) and glandular (20.5%) domains. The distribution of the ESSDAI scores for the entire cohort for each domain is summarized in Supplementary Table S1.
Hydroxychloroquine (HCQ) was prescribed to all patients in our cohort, and three of them were treated with HCQ alone. Regarding the treatment regimen given at the time of diagnosis, 36 patients were prescribed oral glucocorticoids (GCs), and 12 (30.7%) of them were prescribed mycophenolate mofetil (MMF) initially. Six patients on GCs and HCQ were prescribed MMF due to disease flares or relapse during GC tapering or spontaneous withdrawal of GCs. MMF was given as maintenance therapy to four patients using CYC, and a substitute of CsA was given to one patient with immune haemolytic anaemia and thrombocytopenia when the disease was controlled. A total of 23 (58.9%) patients were prescribed MMF (Supplement Table S1).
Thirty-six (92.3%) patients were followed up for a median time of 23.6 (7.9, 79.5) months, and 3 patients were lost to follow-up. Thirty-one (79.4%) patients were followed up for more than 1 year. Three patients developed SLE at a median follow-up time of 38.8 months. One patient was a 13.3-year-old boy with persistent ANA positivity, emerging proteinuria, low complement and anti-Sm antibody positivity who was diagnosed by renal biopsy with lupus nephritis (LN) II at 13.3 months. The second patient was an 11.6-year-old boy who was diagnosed with SLE based on high titres of ANAs and anti-dsDNA antibody, myocarditis and pericardial effusion, and acute cutaneous lupus presented as a photosensitive lupus rash at 38.8 months. The third patient was an 11.7-year-old girl with persistent high titres of ANAs, emerging low complement, anti-Sm antibody and anti-dsDNA antibody positivity, and mild proteinuria and was then diagnosed by renal biopsy with LN III at 63.8 months. No patient had progressed to lymphoma at the last follow-up.
With respect to the other 28 patients, 26 of them achieved a good response, only two patients still experienced mild rash relapse, and no patients exhibited moderate or severe disease activity. Regarding GC tapering, 11 patients withdrew GCs at a median time of 18 (15, 25) months, 13 patients maintained a small dose of GCs (< 5 mg/d) and tapered to 5 mg/d at a median time of 14 (8, 25) months, two patients persistently did not use GCs, and one patient stopped GCs by herself. One patient tapered GCs to a dose of 7.5 mg/d.
The number of studies on and the number of reported cases of childhood-onset pSS are very limited. The data available to date suggest that pSS is a very rare disease in children. Manuel Ramos-Casals et al.  estimated that the frequency of childhood-onset pSS was approximately 1% of patients with primary SS based on the worldwide data-sharing cooperative merging of preexisting clinical SS databases from the five continents, which was to date the largest multicentre study investigating the clinical characteristics of childhood-onset pSS, confirming that pSS is a disease that is rarely diagnosed in children.
Currently available classification criteria [6, 7] have been developed for adult patients, but they are not well validated in childhood-onset SS. Houghton K et al.  reported that 39% of patients met the AECG criteria and 76% met the proposed paediatric criteria; the authors proposed that the AECG adult classification criteria for pSS should not be applied to children as the sensitivity is unacceptably low. In addition, a recent study by Basiaga ML et al.  showed that the majority of children diagnosed with SS in an international childhood SS cohort did not meet the 2016 ACR/EULAR classification criteria, and the authors emphasized the need for further research, including the creation of paediatric-specific classification criteria. In our cohort, we comprehensively evaluated the existing adult criteria as well as the proposed juvenile pSS criteria , 97.4% of patients fulfilled the ACR/EULAR criteria, 89.7% fulfilled the proposed juvenile pSS criteria and 69.2% fulfilled the AECG criteria. The ACR/EULAR criteria are applicable to any patient with at least one symptom of ocular or oral dryness and consider systemic signs and B-cell activation biomarkers (using the ESSDAI) as inclusion criteria , which allows the diagnosis of systemic and earlier forms of the disease when sicca features are not already present. All but one patient (97.4%) in our series had systemic activity at diagnosis (global ESSDAI score ≥ 1) and was diagnosed with SS according to the presence of SSA autoantibodies and LSG biopsy findings, and the last patient’s diagnosis of SS was made according to the proposed juvenile pSS criteria. The ACR/EULAR criteria performed best in our study and might be optimal for the early diagnosis of and clinical research on childhood-onset pSS when combined with the proposed juvenile pSS criteria.
Based on the findings of previous studies [5, 13, 14, 15, 16, 17], the clinical glandular phenotype of childhood-onset SS is mainly dominated by parotid involvement rather than by sicca features, and the symptoms of dry mouth and eyes mostly appear during the course of the disease and rarely as the first complaint. Data from the Sjögren Big Data Consortium [5, 18] confirm that the systemic phenotype of pSS at diagnosis is strongly influenced by personal determinants such as age, gender, and ethnicity. They revealed that patients with childhood-onset pSS showed the highest mean ESSDAI score and the highest frequencies of systemic disease in 5 (constitutional, lymphadenopathy, glandular, cutaneous and haematological) of the 12 ESSDAI domains in comparison with patients with adult-onset disease. In adults, Black/African American patients had the highest frequencies of activity in the lymphadenopathy, articular, neurological and biological domains; White patients in the glandular, cutaneous and muscular domains; Asian patients in the pulmonary, renal and haematological domains; and Hispanic patients in the constitutional domains. More than half of the patients in our study presented with EGMs, and skin, haematological, hepatic and renal involvement were more predominant than in other studies. As summarized in Table 4, ethnic differences might also play a role.
It is remarkable that one-third of patients in our cohort had abnormal hepatic biochemical indices, while only a few studies have reported the frequency (2.4–10.0%) of abnormal hepatic biochemical indices in children [16, 17]. Hepatic involvement is observed in 27 to 49% of cases of pSS in adults, and half of these patients have overt clinical liver disease. The most common liver diseases are primary biliary cholangitis (PBC) and autoimmune hepatitis (AIH) [19, 20]. Hepatic involvement is also frequently found in patients with childhood-onset pSS; therefore, children with pSS should be monitored to identify clinical liver disease early. Interestingly, one patient in our series was diagnosed with pSS combined with cholestasis, RTA, proteinuria (focal proliferative glomerulonephritis and mild TIN), lower limb peripheral neuropathy and 47,XXX. 47,XXX is a rare event and is significantly increased among patients with SLE and SS. The estimated prevalence of SS with 47,XXX in women was 0.29%, which was 2.9 times and 41 times higher than that in women with 46,XX and that in men with 46,XY . This case supported the link between the presence of extra X chromosome(s) and the development of autoimmune diseases and enriched the phenotype of 47,XXX with autoimmune diseases.
Renal involvement in SS is rare, affecting < 10% of patients (range from ~ 1 to > 30% in different studies and ethnicities of adult patients  and 4.5–19.2% in paediatric patients). Renal involvement in pSS is heterogeneous and ranges from isolated electrolyte disturbances and nephrolithiasis to glomerulonephritis and TIN in both acute and chronic forms, and TIN is the most frequent renal complication of pSS. One-fifth of our case series had renal involvement, and four patients underwent renal biopsy (one was to confirm the severity of TIN, the second was to differentiate with SLE, and the last two were confirmed to have lupus nephritis by biopsy when SLE was suspected during the follow-up period). Kidney biopsy can confirm the severity of TIN to determine the treatment regimen and help in the differential diagnosis, especially when glomerular disease is suspected. A kidney biopsy should be performed as soon as possible to rule out other possible causes, such as lupus nephritis.
In addition, in view of ocular involvement, uveitis should be considered as well, similar to earlier reports [17, 23], and deserves comprehensive and continuously monitored systemic evaluation. SS can cause serious, vision-threatening extraglandular ocular manifestations in addition to dry eye.
When childhood pSS is suspected clinically, an appropriate workup should be performed. With respect to the study of exocrine gland dysfunction, some diagnostic tests used in adults are not validated in children , such as the Schirmer test, unstimulated whole saliva flows, and conjunctival lissamine green staining, due to the limited cooperation of the children and the unavailability of stains. We performed corneal fluorescein staining to determine the presence of lacrimal gland disease, and positive findings were noted in only nine (24.3%) of the 37 children evaluated, suggesting that positive ocular staining may be a later manifestation, consistent with the clinical features of sicca symptoms. The finding of focal lymphocytic sialadenitis on minor labial salivary gland biopsy is specifically suggestive of childhood pSS [24, 25]. In previous studies [5, 13, 14, 15, 16, 17], salivary gland biopsy was positive in 53–100% of children (Table 4), and the frequency in our study increased to 100% among the 97.4% of patients who underwent biopsy, which could explain the high rate of meeting the EUALR criteria in our study, while only 43.6% of children in the study of Basiaga ML et al. underwent LGS biopsies, and nearly half exhibited positive findings . Histopathological analyses should also include the biopsy of other salivary or lacrimal glands if tissue was procured for other purposes, such as to rule out lymphoma.
Salivary gland ultrasound (SGUS) is a noninvasive test that may be used to evaluate the glandular damage of salivary glands in children with Sjögren’s syndrome . Recently, Hammenfors et al.  reported pathological SGUS findings in 41 (61%) of 67 patients with childhood-onset SS and indicated that SGUS findings were associated with hyposalivation and autoantibodies. In the study of Manuel Ramos-Casals , the rate was even higher (94%). In our centre, although five of ten patients with parotid involvement underwent SGUS, abnormal findings were revealed in 100%. SGUS might be an interesting diagnostic tool for identifying patients with pSS in childhood, and further clinical application is needed.
The majority of our patients achieved a good response at a median follow-up time of nearly two years, while three patients (nearly 10%) had SLE at 13.3 months, 38.8 months and 63.8 months. Previous studies published that 7.5–10% of patients with long-standing pSS eventually developed a systemic disorder that fulfilled the criteria for SLE in adults [27, 28]. Similar to paediatric patients, Schuetz C et al.  reported that one in eight (12.5%) children with pSS developed overlapping lupus nephritis one year after the diagnosis of pSS. The coexistence of SS and SLE was first demonstrated in 1959 . Compared with SLE alone, this combined disease of SS-SLE has distinct features with relatively less major internal organ involvement but a more specific immunological profile and more favourable clinical outcomes . Yujiao Y et al. revealed that patients with Sjögren's syndrome that progresses to systemic lupus erythematosus (SS/SLE) had an earlier age of onset and higher incidences of proteinuria and low complement levels than patients with pSS in a retrospective case‒control study. Two of them experienced hypocomplementemia and lupus nephritis; thus, long-term follow-up and careful evaluation for SLE in patients with childhood-onset pSS are recommended, and we should be vigilant with patients with these mentioned clinical and laboratory characteristics, who have a higher risk of developing SS/SLE. No patients in our cohort progressed to lymphoma in a median follow-up of nearly 2 years. The complication of lymphoma is rare but is reported in some children with pSS [31, 32]. Whether the risk is similar to or greater than that in adults is not yet known, and attention to this complication is needed in children with pSS.
The study has some limitations. As this was a retrospective study, we analysed preexisting data obtained from electronic medical records; therefore, recall bias was inevitable. This was a single-centre study of Chinese children, and a larger cohort size based on a multicentre study or national registry system is necessary to better define and understand the natural history of pSS in children and to determine which features accurately predict a diagnosis and progression.
In conclusion, the main presentation of childhood-onset pSS were atypical, and extraglandular manifestations and systemic involvement were more common. Labial salivary gland biopsy is vital for patients with probable pSS. The 2016 ACR/EULAR criteria might be optimal for early diagnosis based on systemic assessment and labial salivary gland biopsy. Some patients with typical pSS may develop SLE over time, and attention is drawn to close monitoring and long-term follow-up.
Availability of data and materials
All data generated or analysed during this study are included in this published article and its supplementary information files.
Primary Sjögren’s syndrome
The American-European Consensus Group
The American College of Rheumatology/European League Against Rheumatism
Systemic lupus erythematosus
Sjögren's syndrome disease activity index
- anti-dsDNA antibody:
Anti-double strand DNA antibody
Erythrocyte sedimentation rate
Labial minor salivary gland
Renal tubular acidosis
Primary biliary cholangitis
Salivary gland ultrasound
Brito-Zeron P, Baldini C, Bootsma H, Bowman SJ, Jonsson R, Mariette X, et al. Sjogren syndrome. Nat Rev Dis Primers. 2016;2:16047.
Mariette X, Criswell LA. Primary Sjogren’s Syndrome. N Engl J Med. 2018;379(1):97.
Ciurtin C, Cho Y, Al-Obaidi M, Jury EC, Price EJ. Barriers to translational research in Sjögren’s syndrome with childhood onset: challenges of recognising and diagnosing an orphan rheumatic disease. The Lancet Rheumatology. 2021;3(2):e138–48.
Virdee S, Greenan-Barrett J, Ciurtin C. A systematic review of primary Sjogren’s syndrome in male and paediatric populations. Clin Rheumatol. 2017;36(10):2225–36.
Ramos-Casals M, Acar-Denizli N, Vissink A, Brito-Zerón P, Li X, Carubbi F, et al. Childhood-onset of primary Sjögren’s syndrome: phenotypic characterization at diagnosis of 158 children. Rheumatology (Oxford). 2021;60(10):4558–67.
Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002;61(6):554–8.
Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM, et al. 2016 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Primary Sjögren’s Syndrome: A Consensus and Data-Driven Methodology Involving Three International Patient Cohorts. Arthritis Rheumatol. 2017;69(1):35–45.
Bartůnková J, Sedivá A, Vencovský J, Tesar V. Primary Sjögren’s syndrome in children and adolescents: proposal for diagnostic criteria. Clin Exp Rheumatol. 1999;17(3):381–6.
Houghton K, Malleson P, Cabral D, Petty R, Tucker L. Primary Sjogren’s syndrome in children and adolescents: are proposed diagnostic criteria applicable? J Rheumatol. 2005;32(11):2225–32.
Schuetz C, Prieur AM, Quartier P. Sicca syndrome and salivary gland infiltration in children with autoimmune disorders: when can we diagnose Sjogren syndrome? Clin Exp Rheumatol. 2010;28(3):434–9.
Seror R, Bowman SJ, Brito-Zeron P, Theander E, Bootsma H, Tzioufas A, et al. EULAR Sjögren’s syndrome disease activity index (ESSDAI): a user guide. RMD Open. 2015;1(1):e000022.
Basiaga ML, Stern SM, Mehta JJ, Edens C, Randell RL, Pomorska A, et al. Childhood Sjögren syndrome: features of an international cohort and application of the 2016 ACR/EULAR classification criteria. Rheumatology (Oxford). 2021;60(7):3144–55.
Hammenfors DS, Valim V, Bica B, Pasoto SG, Lilleby V, Nieto-González JC, et al. Juvenile Sjögren’s Syndrome: Clinical Characteristics With Focus on Salivary Gland Ultrasonography. Arthritis Care Res (Hoboken). 2020;72(1):78–87.
Yokogawa N, Lieberman SM, Sherry DD, Vivino FB. Features of childhood Sjogren’s syndrome in comparison to adult Sjogren’s syndrome: considerations in establishing child-specific diagnostic criteria. Clin Exp Rheumatol. 2016;34(2):343–51.
Fang LH, Zhao Y, Ceng XF. Clinical features of primary Sj(o)gren’s sydrome in childhood. Chinese J Pedistrics. 2004;8(42):568–70.
Cimaz R, Casadei A, Rose C, Bartunkova J, Sediva A, Falcini F, et al. Primary Sjogren syndrome in the paediatric age: a multicentre survey. Eur J Pediatr. 2003;162(10):661–5.
Tomiita M, Saito K, Kohno Y, Shimojo N, Fujikawa S, Niimi H. The clinical features of Sjögren’s syndrome in Japanese children. Acta Paediatr Jpn. 1997;39(2):268–72.
Brito-Zerón P, Acar-Denizli N, Ng WF, Horváth IF, Rasmussen A, Seror R, et al. Epidemiological profile and north-south gradient driving baseline systemic involvement of primary Sjögren’s syndrome. Rheumatology (Oxford). 2020;59(9):2350–9.
Podgórska J, Werel P, Klapaczyński J, Orzechowska D, Wudarski M, Gietka A. Liver involvement in rheumatic diseases. Reumatologia. 2020;58(5):289–96.
Kaplan MJ, Ike RW. The liver is a common non-exocrine target in primary Sjögren’s syndrome: a retrospective review. BMC Gastroenterol. 2002;2:21.
Liu K, Kurien BT, Zimmerman SL, Kaufman KM, Taft DH, Kottyan LC, et al. X Chromosome Dose and Sex Bias in Autoimmune Diseases: Increased Prevalence of 47, XXX in Systemic Lupus Erythematosus and Sjögren’s Syndrome. Arthritis Rheumatol. 2016;68(5):1290–300.
François H, Mariette X. Renal involvement in primary Sjögren syndrome. Nat Rev Nephrol. 2016;12(2):82–93.
Akpek EK, Bunya VY, Saldanha IJ. Sjögren’s Syndrome: More Than Just Dry Eye. Cornea. 2019;38(5):658–61.
Yokogawa N, Lieberman SM, Alawi F, Bout-Tabaku S, Guttenberg M, Sherry DD, et al. Comparison of labial minor salivary gland biopsies from childhood Sjögren syndrome and age-matched controls. J Rheumatol. 2014;41(6):1178–82.
Bautista-Vargas M, Vivas AJ, Tobón GJ. Minor salivary gland biopsy: Its role in the classification and prognosis of Sjögren’s syndrome. Autoimmun Rev. 2020;19(12):102690.
Nieto-González JC, Monteagudo I, Bello N, Martínez-Estupiñan L, Naredo E, Carreño L. Salivary gland ultrasound in children: a useful tool in the diagnosis of juvenile Sjögren’s syndrome. Clin Exp Rheumatol. 2014;32(4):578–80.
Yang Y, Li Z, Wang L, Zhang F. The clinical and laboratory characteristics of Sjögren’s syndrome that progresses to systemic lupus erythematosus: a retrospective case-control study. Int J Rheum Dis. 2013;16(2):173–7.
Zufferey P, Meyer OC, Bourgeois P, Vayssairat M, Kahn MF. Primary systemic Sjögren syndrome (SS) preceding systemic lupus erythematosus: a retrospective study of 4 cases in a cohort of 55 SS patients. Lupus. 1995;4(1):23–7.
Heaton JM. Sjögren’s syndrome and systemic lupus erythematosus. Br Med J. 1959;1(5120):466–9.
Yao Q, Altman RD, Wang X. Systemic lupus erythematosus with Sjögren syndrome compared to systemic lupus erythematosus alone: a meta-analysis. J Clin Rheumatol. 2012;18(1):28–32.
Tesher MS, Esteban Y, Henderson TO, Villanueva G, Onel KB. Mucosal-associated Lymphoid Tissue (MALT) Lymphoma in Association With Pediatric Primary Sjogren Syndrome: 2 Cases and Review. J Pediatr Hematol Oncol. 2019;41(5):413–6.
Collado P, Kelada A, Cámara M, Zeft A, Flagg A. Extranodal marginal zone B cell lymphoma: An unexpected complication in children with Sjögren’s syndrome. Reumatol Clin (Engl Ed). 2018;14(4):227–9.
This work was supported by Children's Hospital of Fudan University [2020ZBDL14].
Ethical approval and consent to participate
The study was approved by the Research Ethics Board of Children’s Hospital of Fudan University [No.(2021)498].
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Additional file 1:
Supplement Table S1. The distribution of the ESSDAI score for each domain of 39 patients with childhood-onset primary Sjögren’s syndrome.
Additional file 2.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Gong, Y., Liu, H., Li, G. et al. Childhood-onset primary Sjögren’s syndrome in a tertiary center in China: clinical features and outcome. Pediatr Rheumatol 21, 11 (2023). https://doi.org/10.1186/s12969-022-00779-3
- Primary Sjögren's syndrome
- Clinical features